Specialty Pharmacy

Myasthenia gravis is a chronic autoimmune disease that causes muscle weakness and fatigue, with 4 main treatment options available.

High-cost novel therapies challenge payers and patients, while biosimilars help balance affordability.

An examination of the 340B Drug Pricing Program's original intent, current challenges, and potential resolutions in today's complex health care landscape.

The application includes data from the Vivacity-MG3 study, demonstrating that individuals who received the drug had superior outcomes compared with the standard of care alone.

Despite questions and controversy around some clinical research, new understandings of the pathophysiology of the disease are pushing treatments forward.

Pharmacists can provide extra resources for patients, including explanations of the therapy options for the patients, the course of therapy, and what patients can expect.

The use of surrogate markers was observed for breakthrough-designated indications that were approved through both traditional pathways and accelerated pathways.

Eight areas of improvement were developed as part of national initiative with stakeholder involvement.

Medication therapy management reimbursement can be a driving factor to work toward statin implementation in this patient group.

The guidance, if finalized, would revise considerations about switching studies for proposed interchangeable biosimilars.

In Finland, season of birth, notably autumn and winter, was associated with the development of asthma and allergic rhinitis.

This designation follows the drug's rare pediatric disease designation in July 2024.

Investigators compare the impact of semaglutide for preserved ejection fraction and reduced ejection fraction, which both have different causes and responses to treatment.

Brandon Newman highlights the need for balanced regulation, transparency, and real-time data access to ensure fair competition and optimal outcomes for pharmacy benefit mangers.

The bispecific CAR T-cell therapy for treatment of multiple sclerosis is the first to target both CD19 and CD20.

These pharmacies bring high-touch specialty pharmacies into local communities for patients with more complex needs.

Brandon Newman discusses the significant influence of the "big 3" pharmacy benefit managers and the key legislative and regulatory efforts around transparency.

The highly potent, selective URAT1 inhibitor may help reduce serum uric acid levels and treat clinically visible tophi.

The biosimilar space continues to grow, with key focuses around retina and oncology, but adoption remains slow in the United States.

Noticing indicators of IVIG non-responsiveness can lead to better outcomes among patients with Kawasaki disease as treatment is adjusted.

Response to intravenous immunoglobulin treatment and analysis of neurofilament light chains in patients could be used as prognostic indicators of Guillain-Barre syndrome.

The authors determined that 40 patients (74.1%) converted from chronic to episodic migraine.

Palopegteriparatide is a prodrug of parathyroid hormone designed to provide continuous exposure of the hormone over a 24-hour dosing period.

Investigators find that this could suggest the biosimilar uptake alone may not be a complete measure of the market competition and lowering prices.

Previously, an independent advisory panel for the FDA rejected the use of MDMA-assisted therapy for posttraumatic stress disorder (PTSD), citing concerns of the reliability of the clinical trial data.

Intravenous Immunoglobulin as a therapy for patients with pyoderma gangrenosum could open new treatment avenues for the rare and challenging condition.

Tirzepatide demonstrates statistically significant improvements in adult patients who have heart failure with preserved ejection fraction and obesity.

The injection adds an additional option to address emergency known or suspected opioid overdoses.

Carbidopa and levodopa extended-release capsules are a novel, oral formulation that combine immediate-release granules and extended-release pellets.

Cholesterol-lowering agents, like statins, reduced the risk of major adverse cardiovascular events and cardiovascular disease in patients with HIV.